UNSPSC 51123705: Indecainide

This classification denotes an antiarrhythmic agent with the molecular formula C20H24N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 3AZF20DM1T chemically known as 9h-fluorene-9-carboxamide, 9-(3-((1-methylethyl)amino)propyl)-, but more commonly known as indecainide, which bears US NIH Compound Identifier 52195. European Medicines Agency schedules Indecainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08171MIG.

UNSPSC 51123705 Indecainide, a Commodity code, classifies individual pharmaceutical active ingredients and finished medications procured by state and local health agencies, fire departments, and cooperative purchasing consortia for emergency medical services, hospital formularies, and public health programs. State and local governments buy specific medications under this code through both individual agency procurement and multistate cooperative purchasing agreements, with solicitations typically requiring pharmaceutical manufacturers or authorized distributors to supply products meeting FDA compliance, cGMP certification, Drug Supply Chain Security Act (DSCSA) requirements, and expiration-dating standards. Issuing bodies include municipal fire departments (Tampa Fire Rescue), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering on behalf of participating state and local facilities in Minnesota and Oregon).

Recent opportunities span Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, seeking advanced life support medications including epinephrine, adenosine, labetalol, and diltiazem vials for Tampa Fire Rescue with a response deadline of April 8, 2026, an estimated contract value of $40,000, and a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount capped at $10,000. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration issued RFP S1070000015802 through MMCAP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed to participating state and local facilities across multiple states, with proposals due March 26, 2026, requiring vendors to maintain relationships with AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co. as authorized wholesalers, and evaluation weighted 75 percent on price competitiveness.